June 25, 2010
The initiation of a multinational, randomized, double-blind Phase IIIb trial, PALLAS to assess the potential clinical benefit of Multaq® (dronedarone) in over 10,000 patients with permanent atrial fibrillation (AF) to reduce major adverse cardiovascular events, was announced during the Heart Rhythm Society’s 31st Annual Scientific Sessions.
Log in or Register now.
Sign up for our regular email newsletters & be the first to know about fresh articles and site updates.